Sir Andrew Witty to retire from GSK in March 2017


In the publication of its 2015 Annual Report to shareholders, GSK plc announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017. The Board has agreed that he will retire on 31st March 2017. The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role. 

Sir Philip Hampton, Chairman, said: “Andrew's retirement next year will represent the culmination of 32 years of service and leadership to GSK and the industry. We will thank Andrew more formally for his tremendous dedication and contribution next year. In the meantime, we will now start a formal process to appoint his successor, whilst also ensuring the Group remains focused on execution of its strategy to drive growth and performance.”

Press releases

Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

•150 healthy adult and elderly participants expected to be enrolled in Phase 1 study <br/> •COVID-19 vaccine candidate to be evaluated in combination with GSK’s pandemic adjuvant system and Dynavax’s CpG 1018 adjuvant following promising preclinical study results <br/> •Preliminary safety and immunogenicity results expected in August 2020 <br/> •Global Phase 2b/3 vaccine efficacy study is in planning stage, targeting initiation by year-end 2020

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

•Interim analysis from HPTN 083 study shows investigational, long-acting injectable cabotegravir (CAB LA) administered every two months is 69% more effective than daily pills in preventing HIV acquisition <br/> •Participants who were in the daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg (FTC/TDF) tablet arm of the study will be offered CAB LA <br/>